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Ghrelin is released in response to fasting, such that circulating levels are highest immediately prior to meals. Bone turnover is
acutely responsive to the fed state, with increased bone resorption during fasting and suppression during feeding. The current
study investigated the hypothesis that ghrelin regulates the activity of bone cells. Ghrelin increased the bone-resorbing activity of
rat osteoclasts, but did not alter osteoclast diﬀerentiation in a murine bone marrow assay nor bone resorption in ex vivo calvarial
cultures. Ghrelin showed mitogenic activity in osteoblasts, with a strong eﬀect in human cells and a weaker eﬀect in rat osteoblasts.
The expression of the human ghrelin receptor, GHSR, varied among individuals and was detectable in 25–30% of bone marrow
and osteoblast samples. However, the rodent Ghsr expression was undetectable in bone cells and cell lines from rat and mouse.
These data suggest that elevated levels of ghrelin may contribute to the higher levels of bone turnover that occurs in the fasted
state.
1.Introduction
Bone is constantly remodeled through the actions of bone-
forming osteoblasts and bone-resorbing osteoclasts. Bone
turnover is acutely responsive to food intake, with bone re-
sorption increased during fasting and suppressed during
feeding [1, 2]. Numerous factors, such as nutritional content
or size of meals, may play a role in this relationship and there
is evidence that some gut hormones, such as glucagon-like
peptide-2 [3, 4], also aﬀect the normal postprandial reduc-
tion of bone resorption.
Ghrelin is a 28-amino-acid peptide hormone primarily
synthesized by the stomach and released in response to
fasting, such that circulating levels, which range from 100–
120pmol/L in rats [5] or 90–240pmol/L in humans [6], are
highest immediately prior to meals and fall upon feeding
[7, 8]. Two forms of ghrelin are found in the circulation: n-
octanoyl ghrelin, which is acylated with an n-octanoyl group
on serine residue 3, and des-acyl ghrelin [5]. The n-octan-
oylated form of ghrelin binds the GH secretagogue receptor
(GHSR1a), increases food intake [9–11], and induces release
of growth hormone from the pituitary via the hypothalamus
[5, 12] as well as by directly acting on the pituitary [5]. The
major form of circulating ghrelin is des-acyl ghrelin, which
does not signal through GHSR1a and was considered to be
inactive, although recent studies suggest that des-acyl ghrelin
has some biological activity [13, 14]. The ghrelin receptor,
GHSR, is a seven transmembrane-domain G-protein cou-
pled receptor [15]. Two transcripts are produced from the
human GHSR gene by alternative splicing: GHSR1a encodes
the functional receptor, and GHSR1b, which is truncated
after transmembrane domain 5, appears to be unable to
stimulate intracellular signaling pathways [15].
The activity of ghrelin to stimulate feeding produced a
great interest in this peptide as a potential drug target. Re-
ceptor antagonists or inverse agonists have been developed
for potential treatments of obesity by the induction of
satiety [16, 17] and ghrelin and receptor agonists have been
considered for treatment of cancer-related cachexia [18, 19].
In addition, ghrelin has been investigated for a therapeutic
role in cardiovascular disease [20, 21] because of the
expression of the ghrelin receptor in vascular smooth muscle
cells of the cardiovascular system [22].2 International Journal of Peptides
A number of studies investigated the eﬀects of ghrelin in
skeletal tissue. Expression of the ghrelin receptor, GHSR1a,
has been demonstrated by reverse transcription-PCR, im-
munohistochemistry, and western blot analysis in several
osteoblasts and osteoblastic cell lines [23, 24]a n das t u d yo f
the expression of GHSR1a in human tissues demonstrated a
weak positive signal in bone marrow [25]. In vitro studies
showed eﬀects of ghrelin in primary osteoblast-like cells and
cell lines, with highly variable responses in proliferation, dif-
ferentiation, and survival assays [23, 24, 26–28]. Osteoclast
response to ghrelin has never been investigated previously.
However, as a growth hormone secretagogue, ghrelin is likely
to have an indirect eﬀect on osteoclasts, as growth hormone
increases formation and function of osteoclasts isolated from
mouse or rabbit bone marrow or spleen [29].
The aim of the current study was to further investigate
the activity of ghrelin in bone cells, and in particular its pos-
sible role in the acute stimulation of bone resorption that
occurs during fasting. We used assays of both osteoclast for-
mation and mature osteoclast function to investigate ghre-
lin’s role in bone resorption, in addition to testing the eﬀects
of ghrelin on osteoblasts, and investigating the expression of
the ghrelin receptor in bone cells.
2. Methods
2.1. Materials. Acylated ghrelin with n-octanoyl at serine
residue 3 was purchased from American Peptide Company
(Sunnyvale, CA) and this form was used exclusively in all
studies. BSA was purchased from ICPbio International, Ltd
(Auckland, New Zealand). Gibco brand FBS and media were
used (Invitrogen, Auckland, New Zealand). Tritiated thymi-
dine was purchased from NZ Scientiﬁc, Ltd (Auckland, New
Zealand). Tartrate-resistant acid phosphatase (TRAP) stain-
ing kit, 1,25-dihydroxyvitamin D3, osteoprotegerin (OPG),
and salmon calcitonin were purchased from Sigma (NSW,
Australia).
2.2. Cell and Tissue Samples from Human Subjects and from
Animals. Animals were purchased from the Vernon Jensen
Unit of the University of Auckland. All animal procedures
were approved by the Animal Ethics Committee of our insti-
tution. Human bone samples were collectedfrom consenting
subjects undergoing hip and knee arthroplasty for arthritis.
The study had the approval of the local institutional review
board.
2.3. Primary Osteoblast Proliferation, Diﬀerentiation and
Apoptosis Assays. Rat osteoblasts were isolated from 20-day
fetal rat calvariae, as previously described [30, 31]. For
proliferation assays, cells were seeded into 24-well plates in
5% FBS/MEM/5μg/mL ascorbic-acid-2-phosphate (AA2P)
for 24h. Cells were growth-arrested in 0.1% BSA/MEM/
5μg/mL AA2P for 24 hours. Fresh media and experimental
compounds were then added for a further 24 hours. Cells
were pulsed with 3H-thymidine 6 hours before the end of the
experimental incubation. The experiment was terminated
and cell counts or thymidine incorporation determined.
T h e r ew e r es i xw e l l si ne a c hg r o u p ,a n de a c he x p e r i m e n tw a s
repeated three or four times. Mineralization and apoptosis
assays were carried out on this cell type as previously
described [31]. Mineralization was determined by von Kossa
stain, and apoptosis by terminal deoxynucleotidyl transfer-
ase-mediated deoxyuridine triphosphate nick end labeling
(TUNEL).
Cultures of primary human osteoblasts were prepared
using normal human trabecular bone. Osteoblasts were
grown from enzyme-treated bone chips, using a modiﬁed
m e t h o do fR o b e ya n dT e r m i n e[ 32] and treated with ex-
perimental compounds 24 or 48 hours prior to end of the
incubation. The experiments were carried out three times
with similar results.
2.4. Bone Marrow Culture. Bone marrow was obtained from
the long bones of normal Swiss CD-1 male mice aged 4–
6 weeks, as previously described [30, 31]. Brieﬂy, marrow
cells were grown in 48-well plates and on days 0, 2, and
5, 1,25-dihydroxyvitamin D3 (10−8 M) was added to all
wells. On days 2 and 4, cultures were fed with 0.5mL fresh
mediumcontainingtestsubstances.Recombinanthumanos-
teoprotegerin (10ng/mL) was included as a positive control
for inhibition of osteoclastogenesis. After 7 days of culture,
TRAP-positive multinucleated cells (containing three or
more nuclei) were counted in all wells. There were at least
eight wells for each group, and the experiment was carried
out four times with similar results.
2.5. Mature Isolated Osteoclast Culture. Rat osteoclasts were
isolated from the long bones of 1-2-day-old rats, as pre-
viously described [30, 31] and incubated on bovine bone
slices with test substances or vehicle for 24 hours. After
incubation, the bone slices were ﬁxed and stained for TRAP.
The potent inhibitor of osteoclast activity, salmon calcitonin
(10−10 M), was used as a positive control. The number of
TRAP-positive multinucleated cells containing three or more
nucleioneachboneslicewascounted,thecellswereremoved
by gentle scrubbing, and then the bone slices were stained
for 30 seconds with toluidine blue. After several washes in
water, the bone slices were dried and assessed for the pits
excavated by the osteoclasts, using reﬂected light microscopy
with metallurgic lenses. The results for each bone slice
were expressed as the ratio of the number of pits to the
number of osteoclasts. There were 6–8 bone slices in each
group and the experiment was carried out more than three
times.
2.6. Bone Organ Culture. Hemicalvariae labeled in vivo
with 45Ca were collected as described previously [31]a n d
incubated with experimental substances or vehicle for 48
hours. Calcium release was assessed and used to calculate the
percent of 45Ca released over total 45Ca injected per animal
(3μCi), and 3H-thymidine incorporation was measured
as an indicator of cell proliferation. Parathyroid hormone
(PTH) (10−8 M) was used as a positive control. There were
ﬁvetosevenhemicalvariaeineachgroup,andtheexperiment
was carried out more than three times.International Journal of Peptides 3
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Figure 1: Ghrelin increases bone resorption by mature rat
osteoclasts. Osteoclasts were incubated on bovine bone slices for
24 hours, and the number of TRAP-positive multinucleated cells
on each bone slice was counted. Cells were then removed, the
bone slices were stained with toluidine blue, and the number of
excavated pits was determined by reﬂected light microscopy. The
results are expressed as the ratio of the number of pits to the
number of osteoclasts on a bone slice, with 6–12 bone slices in each
group. MNC: multinucleated cells. sCT: salmon calcitonin (positive
control). Data are mean ± SEM; ∗indicates P<0.05 compared to
untreated control.
2.7. RNA Isolation, Reverse Transcription, and Quantitative
PCR . RNA was collected from ﬂash frozen mouse hypotha-
lamic tissue or cultured cells with Qiagen RNeasy minikits,
and genomic DNA was removed using the RNase-free DNase
set (Qiagen) according to manufacturer’s instructions. RNA
samples collected from cell cultures grown from human
osteoblast and bone marrow have been previously described
[33].cDNAwassynthesizedwithSuperscriptIII(Invitrogen)
andusedformultiplexreal-timePCRinABIPRISM7900HT
Sequence Detection Systems (Applied Biosystems). Primers
and probe sets were purchased as TaqMan Gene Expression
Assays (Applied Biosystems) for mouse Ghsr,r a tGhsr, and
human GHSR. All probes used to detect target genes were
labeled with FAM and 18S rRNA endogenous control probe
was VIC labeled. The ΔΔCt method was used to calculate the
relative levels of expression [34].
2.8. Statistics. Data were analyzed using ANOVA with post
hoc Dunnett’s tests or Student’s t-test as indicated for
experiments with 2 or more treatments. Student’s t-test was
used where a single treatment was analyzed versus vehicle. A
5% signiﬁcance level (P<0.05) is used throughout. Data are
presented as means ± SEM, unless indicated otherwise.
3. Results
3.1. The Eﬀects of Ghrelin on Osteoclast Diﬀerentiation and
Activity. We used a number of in vitro experimental systems
to study the eﬀects of ghrelin on osteoclast diﬀerentiation
and activity. Mature osteoclasts were isolated from long
bones of 1-2-day-old rats and cultured on slices of bovine
bone. Ghrelin at a concentration of 1nM induced a 30%
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Figure 2:Osteoclastdiﬀerentiationinmousebonemarrowcultures
is not aﬀected by ghrelin. Bone marrow cells were cultured for 7
days with experimental substances or vehicle. Cells were ﬁxed and
stained and the number of TRAP positive cells with three nuclei
or more was determined in each well. MNC: multinucleated cells,
OPG: osteoprotegerin (positive control). Data are mean ± SEM;
∗indicates P<0.05 compared to untreated control.
increase in the number of pits excavated by osteoclasts,
whereas at 10nM there was only a 15% increase which
was not signiﬁcantly diﬀerent from the control (Figure 1).
Osteoclast diﬀerentiation was investigated using a murine
bone marrow assay, where the mixed population of cells
from the bone marrow is cultured in the presence of 1,25-
dihydroxyvitamin D3 that promotes osteoclast formation.
The addition of ghrelin at concentrations of 0.1–10nM
during the seven-day incubation period had no eﬀect on the
numberofosteoclastsascomparedtocontrol(Figure 2).The
activity of ghrelin was also tested in an ex vivo organ culture
of mouse calvariae. This experimental system is investigating
osteoclast activity rather than development as there is only
a minimal number of preosteoclasts in the calvariae. The
ability of osteoclasts to resorb bone, as measured by % 45Ca
release, was unaﬀected by ghrelin (Figure 3). Measurement
of 3H thymidine incorporation in the same cultures showed
no diﬀerence in cell proliferation in the presence of ghrelin
(data not shown).
3.2. The Eﬀects of Ghrelin on Osteoblasts. Human primary
osteoblasts incubated for 24 or 48 hours in the presence
of 0.1nM ghrelin showed a 2-fold increase in proliferation,
as measured by thymidine incorporation (Figure 4). Ghrelin
weakly induced cell proliferation in primary rat osteoblasts,
with a 1.1-1.2-fold stimulation of thymidine incorporation
(Figure 5(a)) and a similar, modest increase in cell numbers
(Figure 5(b)).
We also investigated ghrelin’s eﬀects on osteoblast
diﬀerentiation. Primary rat osteoblasts were cultured for
21 days in media supplemented with L-ascorbic acid-2-
phosphate and β-glycerophosphate, and mineralized bone
nodule formation was measured by Von Kossa stain. Ghrelin
had no eﬀect on osteoblast diﬀerentiation in this assay (data
not shown). The eﬀect of ghrelin on osteoblast survival was4 International Journal of Peptides
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Figure 3: Osteoclast activity in mouse calvarial culture is not
aﬀected by ghrelin. Calvariae labeled in vivo with 45Ca were
collected and incubated ex vivo with experimental substances or
vehicle for 48 hours. Values are expressed as percent released
45Ca detected over total 45Ca injected (3μCi). PTH: parathyroid
hormone (positive control). Data are mean ± SEM; ∗indicates P<
0.05 compared to untreated control.
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Figure 4: Ghrelin is mitogenic to primary human osteoblasts.
Osteoblasts cultured from human trabecular bone were growth-
arrested in 0.1% BSA for 24 hours. Ghrelin was added for 24 or
48 hours, and cells were pulsed with 3H-thymidine for the last 24
hours of the incubation. Data are mean ± SEM; ∗indicates P<0.05
compared to untreated control by t-test.
investigated using a TUNEL assay. Apoptosis was induced
in primary rat osteoblast by serum withdrawal, and the
cells were incubated for a further 24 hours in the presence
of ghrelin or controls. There was no signiﬁcant change in
the number of apoptotic bodies between the treatment and
control wells, indicating that ghrelin had no eﬀect on cell
survival in this experimental system (data not shown).
3.3. The Expression of Ghrelin Receptor, GHSR, in Bone Cells
from Human, Rat, and Mouse Origin. Quantitative PCR was
Table 1: Ghrelin receptor expression in bone.
This study Method Result
Primary tissue
Human osteoblasts (n = 10) Quantitative
PCR
3/10
positive
Human bone marrow (n = 16) 4/16
positive
Mouse bone marrow Negative
Rat osteoblastic cells Negative
Mouse hypothalamus Positive
Cell lines
Mouse osteoblastic MC3T3-E1 Negative
Mouse macrophage RAW264.7 Negative
Kim et al. [23]
Primary Tissue
Rat osteoblastic cells
Western blot Positive Mouse osteoblastic cells
Rat brain
Cell lines
Mouse osteoblastic MC3T3-E1
Positive Mouse preadipocytic 3T3-L1 RT-PCR,
Western blot Rat ROS17/2.8 osteogenic sarcoma
Rat UMR-106 osteogenic sarcoma
Maccarinelli et al. [24]
Primary Tissue
Rat osteoblastic cells RT-PCR,
Western blot Positive
Ueberberg et al. [25]
Primary Tissue
Human bone marrow Quantitative
PCR, IHC Positive
Delhanty et al. [27]
Primary Tissue
Human bone marrow (n = 2) Quantitative
PCR Positive
Fukushima et al. [28]
Primary Tissue
Rat osteoblastic cells RT-PCR,
IHC Positive
Rat femur IHC Positive
Cell lines
Rat UMR-106 osteogenic sarcoma RT-PCR Positive
Guan et al. [35]
Primary Tissue
Rat bone marrow RPA Negative
RT-PCR: reverse transcription PCR. IHC: immunohistochemistry. RPA,
ribonuclease protection assay.
used to determine the expression of GHSR in bone cells. The
GHSR TaqMan probe we used is designed to hybridize to a
common sequence which is included in both of the alterna-
tively splices products of the gene: GHSR1a and GHSR1b.
We tested the expression of GHSR in RNA extracted fromInternational Journal of Peptides 5
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Figure 5: Ghrelin is weakly mitogenic to primary rat osteoblasts. Osteoblasts cultured from rat calvariae were growth-arrested in 0.1% BSA
for 24 hours. Fresh media and experimental compounds were then added for a further 24 hours. (a) Thymidine incorporation: cells were
pulsed with 3H-thymidine for the last 6 hours of incubation (ANOVA P = 0.018). (b) Cell counts (ANOVA P = 0.076). Data are mean ±
SEM; ∗indicates P<0.05 compared to untreated control by t-test.
human primary osteoblasts and bone marrow samples and
found that the expression varies among individuals, with 3
out of 10 osteoblast samples and 4 out of 16 bone marrow
samples showing a positive ampliﬁcation signal. Rat primary
osteoblast and mouse bone marrow cells showed no expres-
sion of Ghsr. We also tested the mouse osteoblastic cell line
MC3T3-E1, collecting RNA samples on diﬀerent days during
thediﬀerentiationofthecellsintomatureosteoblastsinvitro
and found no expression of Ghsr. RNA samples collected
from the murine macrophage cell line RAW264.7,w h i c h
diﬀerentiate in vitro into osteoclasts, were also negative for
Ghsr. RNA extracted from mouse hypothalamic tissue which
was used as positive control showed high levels of Ghsr
expression (Table 1).
4. Discussion
The gastric hormone ghrelin is primarily secreted from the
stomach in response to hunger or fasting and it induces
growth hormone secretion and food intake, most likely via
activation of type 1a receptors in the arcuate nucleus of
the hypothalamus. Here we investigated the direct impact of
ghrelin on bone cells to expand on previous in vitro studies
of ghrelin and show the ﬁrst data regarding ghrelin’s impact
on osteoclasts in vitro. The ﬁnding that ghrelin stimulates
mature osteoclast activity to resorb bone suggests a possible
direct link between increased levels of circulating ghrelin and
stimulation of bone resorption induced by fasting.
Ghrelin does not appear to be a primary requirement for
bone formation and remodeling. In mouse models lacking
either ghrelin or the ghrelin receptor, there are no known
changes to the skeleton. Mice lacking ghrelin [36]a r en o rm a l
in size and weight compared to their littermate controls,
showingneitherdwarﬁsmnorobesityandnochangeinbone
mineral content or density. Mice lacking the ghrelin receptor
have normal body size with slightly reduced body weight
though there is no change in their bone mineral content or
density [37]. The lack of changes in these null models sug-
gests a redundancy in the ghrelin-growth hormone system.
Overexpression of ghrelin from the brain and stomach of
transgenic mice does not induce any changes in body size,
though these animals have increased food intake, while the
impact on bone is unknown [38].
Our study shows stimulation of osteoblast proliferation
in primary cells derived from rat calvariae and from human
bone. Stimulation of proliferation in similar cultures from
rat and human origin has been demonstrated before [24,
27, 28]. However, the ﬁnding that ghrelin had no eﬀect on
osteoblast diﬀerentiation and apoptosis varies from what
has been shown by some of the other groups: increased
osteoblast diﬀerentiation was determined in rat primary
osteoblasts and in MC3T3-E1 cells [23, 24, 28], whereas
in the human osteoblast cell line SV-HFO ghrelin had no
eﬀect on diﬀerentiation [27], similar to what we found in the
current study. Kim et al. [23] showed that ghrelin inhibits
apoptosis in MC3T3-E1 cells, in contrast to our observations
that ghrelin had no eﬀect on apoptosis in primary rat os-
teoblasts. A study of the eﬀect of ghrelin on apoptosis in
rat osteoblasts and various other primary cells of rat and
human,aswellasinhumanaldosteronomaandhumanadre-
nocortical carcinoma-derived cell lines, showed that ghrelin
did not aﬀect apoptotic rate of normal cells, but signiﬁcantly
enhanced apoptosis in tumor-derived cells [26]. Thus, the
eﬀect of ghrelin on apoptosis appears to depend on the cells
tested, with reports of inhibition, activation, and no eﬀecton
apoptosis in diﬀerent cells.
Ghrelin receptors are widely distributed and have pre-
viously been shown to be present in bone cells and tissue
by reverse-transcription PCR, western blots and immuno-
histochemistry [23–25, 28]. We used real-time PCR to test
the expression of Ghsr in primary rat osteoblasts and mouse
bone marrow cells, and in the mouse cell lines MC3T3-E16 International Journal of Peptides
and RAW264.7, but failed to ﬁnd any expression of the ghrel-
in receptor. This was not due to technical problems, as
expression was robust in hypothalamic positive controls. In
contrast to the lack of expression in bone cells of rodents,
we found that bone cells from humans expressed the ghrel-
in receptor, although we could only detect low levels of
expression in less than half of the osteoblast and bone mar-
row samples tested. The expression of GHSR in cells from
26 diﬀerent patients showed individual variability that
could perhaps explain some inconsistencies in results from
diﬀerent studies. Delhanty et al. [27] used TaqMan assays
that were designed to distinguish between GHSR1a and
GHSR1b to determine the expression of GHSR in bone
samples from two patients and found that only the GHSR1b
transcript was detectable. It would be of interest to test if
the human RNA samples used in our study also express
exclusively the GHSR1b splice variant.
The fact that ghrelin promotes proliferation of rat
osteoblasts though these cells do not express the ghrelin
receptor may suggest the existence of an alternative signaling
pathway for ghrelin and raises the possibility of unreported
negative results or age-dependent expression, as seen in
adipocytes [39]. Previous studies have also indicated that
an additional, GHSR1a-independent pathway might be acti-
vated by ghrelin in a cardiomyocyte cell line not expressing
GHSR [40]. Here, ghrelin was found to promote prolifera-
tion of human osteoblasts, although these cells express only
the GHSR1b isoform, which is considered to be inactive
[27]. In a unilateral bone marrow infusion experimental
system, Thompson et al. [14] showed that des-acyl and n-
octanoylated ghrelin were active whereas a potent synthetic
GHSR1a agonist was ineﬀective, and so the authors suggest
a pathway involving a receptor other than GHSR1a. At least
in the case of des-acyl ghrelin, Chen et al. [41] found that
it may act via a corticotropin releasing factor receptor, but
there do not currently appear to be any studies investigating
an alternative signaling pathway for n-octanoylated ghrelin.
This is a worthwhile goal for the future of this ﬁeld.
Since its discovery in 1999 [5], ghrelin has been the focus
of a large number of studies. The activity of ghrelin in bone
hasbeeninvestigatedinvivoandinvitro,buttheresultshave
not always been consistent. Our investigations of the eﬀects
of n-octanoylated-ghrelin in bone cells in vitro provide the
ﬁrst data in support of a direct eﬀect of ghrelin to promote
bone resorption by osteoclasts.
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